MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Cited by (1,001)

Items 501–600 of 1,001

1. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
   Stephen W. Jarantow, Barbara S. Bushey, José R. Pardinas, Ken Boakye, Eilyn R. Lacy, Renouard Sanders, Manuel A. Sepúlveda, Sheri L. Moores, Mark L. Chiu · 2015 · Journal of Biological Chemistry
2. IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
   Romaine Ingrid Fernando, Duane H. Hamilton, Charli L. Dominguez, Justin M. David, Kristen K. McCampbell, Claudia Palena · 2016 · Oncotarget
3. Targeting the hepatocyte growth factor/Met pathway in cancer
   Dinuka M. De Silva, Arpita Roy, Takashi Kato, Fabiola Cecchi, Young H. Lee, Kunio Matsumoto, Donald Paul Bottaro · 2017 · Biochemical Society Transactions
4. CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway
   Chunjie Wen, Yaji Li, Yutang Huang, Nan Wang, Shuai He, Meihua Bao, Hong‐Hao Zhou, Lanxiang Wu · 2022 · The International Journal of Biochemistry & Cell Biology
5. Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
   Jason D. Katz, James P. Jewell, David J. Guerin, Jongwon Lim, Christopher J. Dinsmore, Sujal V. Deshmukh, Bo‐Sheng Pan, C. Gary Marshall, Wei Lu, Michael D. Altman et al. · 2011 · Journal of Medicinal Chemistry
6. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
   David S. Hong, Patricia Mucci LoRusso, Omid Hamid, Filip Jankú, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily W. Chan, Tanios Bekaii‐Saab, Shirish M. Gadgeel, Robert D. Loberg et al. · 2018 · Clinical Cancer Research
7. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing
   Philipp Sebastian Jurmeister, Dido Lenze, Erika Gebel Berg, Stefanie Mende, Frank Schäper, Udo Kellner, Hermann Herbst, Christine Sers, Jan Budczies, Manfred Dietel et al. · 2014 · Lung Cancer
8. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
   Yoshio Tomizawa, Yuka Fujita, Atsuhisa Tamura, Masahiro Shirai, Satoshi Shibata, Tsutomu Kawabata, Takuo Shibayama, Shimao Fukai, Masaaki Kawahra, Ryusei Saito · 2009 · Lung Cancer
9. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer
   Rudi Bao, Cheng-Jung Lai, Da-Gong Wang, Hui Qu, Ling Yin, Brian M. Zifcak, Xu Tao, Jing Wang, Ruzanna Atoyan, Maria Samson et al. · 2009 · Molecular Cancer Therapeutics
10. MET receptor tyrosine kinase as a therapeutic anticancer target
    Christine Marie Stellrecht, Varsha V. Gandhi · 2008 · Cancer Letters
11. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
    Hiroki Sato, Kazuhiko Shien, Shuta Tomida, Kazuhiro Okayasu, Ken Suzawa, Shinsuke Hashida, Hidejiro Torigoe, Mototsugu Watanabe, Hiromasa Yamamoto, Junichi Soh et al. · 2017 · Scientific Reports
12. Targeted therapies for advanced non-small cell lung cancer
    Xiaojuan Ai, Xialing Guo, Jun Wang, Andreea Lucia Stancu, Patrick M. N. Joslin, Dianzheng Zhang, Shudong Zhu · 2018 · Oncotarget
13. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
    Yi‐Nan Liu, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, Tzu-Hsiu Tsai, Chien‐Hung Gow, Yih‐Leong Chang, Jin‐Yuan Shih · 2019 · International Journal of Cancer
14. Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy
    Paul Dent, David T. Curiel, Paul B. Fisher, Steven Grant · 2009 · Drug Resistance Updates
15. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
    Peter Stephen Savas, Brett G.M. Hughes, Benjamin Solomon · 2013 · Europe PMC (PubMed Central)
16. c-MET Inhibitors in the Treatment of Lung Cancer
    Joanna Goździk-Spychalska, Katarzyna Szyszka-Barth, Łukasz Spychalski, Katarzyna Ramlau, J Wójtowicz, Halina Batura‐Gabryel, Rodryg Ramlau · 2014 · Current Treatment Options in Oncology
17. Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer
    Jenn‐Yu Wu, Jin‐Yuan Shih, Chih‐Hsin Yang, Kuan‐Yu Chen, Chao‐Chi Ho, Chong‐Jen Yu, Pan‐Chyr Yang · 2009 · International Journal of Cancer
18. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
    Sariah Liu, Mina Nikanjam, Razelle Kurzrock · 2016 · Oncotarget
19. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
    Hannah A. Scarborough, Barbara A. Helfrich, Matias Casás‐Selves, Alwin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik Choon Tan, Daniel C. F. Chan, Zhiyong Zhang, Vadym Zaberezhnyy et al. · 2016 · Clinical Cancer Research
20. Understanding c-MET signalling in squamous cell carcinoma of the head & neck
    Petr Szturz, Éric Raymond, Chloé Abitbol, Sébastien Albert, Armand D.E. Gramont, Sandrine J. Faivre · 2017 · Critical Reviews in Oncology/Hematology
21. Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer
    Ken Suzawa, Michael David Offin, Adam Jacob Schoenfeld, Andrew J. Plodkowski, Igor Odintsov, Daniel Lu, William Wirt Lockwood, Maria E. Arcila, Charles M. Rudin, Alexander Edward Dela Cruz Drilon et al. · 2019 · JCO Precision Oncology
22. Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
    Spaans, Johanna N., Goss, Glenwood D. · 2014 · Frontiers in Oncology
23. Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets
    Katherine Chang, Anand B. Karnad, Shujie Zhao, James W. Freeman · 2015 · Oncotarget
24. Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion
    Timothy G. Whitsett, Emily Cheng, Landon J. Inge, Kaushal V. Asrani, Nathan M. Jameson, Galen H. Hostetter, Glen J. Weiss, Christopher B. Kingsley, Joseph C. Loftus, Ross Macrae Bremner et al. · 2012 · American Journal Of Pathology
25. Clinical perspective of afatinib in non-small cell lung cancer
    Xiaofeng Chen, Quan Zhu, Lingjun Zhu, Dong Pei, Yiqian Liu, Yongmei Yin, Martin Schüler, Yongqian Shu · 2013 · Lung Cancer
26. Current concepts on the molecular pathology of non-small cell lung carcinoma
    Junya Fujimoto, Ignacio Ivan Wistuba · 2014 · Seminars in Diagnostic Pathology
27. A Urokinase Receptor–Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma
    Jill Wykosky, Jingjing Hu, German G. Gomez, Tiffany E. Taylor, Genaro R. Villa, Donald P. Pizzo, Scott R. VandenBerg, Amy Haseley Thorne, Clark C. Chen, Paul S. Mischel et al. · 2014 · Cancer Research
28. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
    Pasi Antero Janne, Alice Tsang Shaw, D. Ross Camidge, Giuseppe Giaccone, S. Martin Shreeve, Yiyun Tang, Zelanna Goldberg, Jean‐François Martini, Huiping Xu, Leonard Philip James et al. · 2016 · Journal of Thoracic Oncology
29. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
    Tony S.K. Mok, Sarayut Lucien Geater, Wu‐Chou Su, Eng-Huat Tan, James Chih‐Hsin Yang, Gee‐Chen Chang, May Han, Philip B. Komarnitsky, Francis C. Payumo, Jennifer E. Garrus et al. · 2016 · Journal of Thoracic Oncology
30. Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways
    Weibo Chen, Junhua Wu, Hua Shi, Zhong‐Xia Wang, Guang Zhang, Yin Cao, Chunping Jiang, Yitao Ding · 2014 · BioMed Research International
31. Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer
    Hirohito Yamaguchi, Jennifer L. Hsu, Mien‐Chie Hung · 2012 · Frontiers in Oncology
32. Curcumin Lowers Erlotinib Resistance in Non-Small Cell Lung Carcinoma Cells With Mutated EGF Receptor
    Shanqun Li, Zilong Liu, Fen Zhu, Xiaohong Fan, Xiaodan Wu, Heng Zhao, Liyan Jiang · 2014 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
33. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
    Quincy Siu-Chung Chu · 2020 · Therapeutic Advances in Medical Oncology
34. Identification of potential diagnostic and prognostic biomarkers for LUAD based on TCGA and GEO databases
    Qiangqiang Zheng, Shihui Min, Qinghua Zhou · 2021 · Bioscience Reports
35. The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target
    Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio · 2022 · Journal of Oncology
36. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
    Zixi Wang, Yurou Xing, Bingjie Li, Xiaoyu Li, Bin Liu, Yongsheng Wang · 2022 · Molecular Biomedicine
37. Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models
    Sean Ekins, Robert C. Reynolds, Scott Gary Franzblau, Baojie Wan, Joel S. Freundlich, Barry A. Bunin · 2013 · PLoS ONE
38. Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Takuya Araki, Hideaki Yashima, Kimihiro Shimizu, Tohru Aomori, Tadahiro Hashita, Kyoichi Kaira, Tomonori Nakamura, Koujirou Yamamoto · 2012 · Clinical Medicine Insights Oncology
39. Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer
    Alexandra B. Lantermann, Dongshu Chen, Kaitlin McCutcheon, Greg Hoffman, Elizabeth Frias, David A. Ruddy, Daniel P. Rakiec, Joshua M. Korn, Gregory McAllister, Frank P. Stegmeier et al. · 2015 · Cancer Research
40. Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update
    Ayodele Ayoola, Amit Barochia, Kiran Belani, Chandra Prakash Belani · 2012 · Cancer Investigation
41. Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Aarif Ahsan · 2015 · Advances in experimental medicine and biology
42. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
    Yang-ling Li, Ke Ding, Xiu Hu, Lin‐wen Wu, Dongmei Zhou, Mingjun Rao, Neng‐ming Lin, Chong Zhang · 2019 · Journal of Cellular and Molecular Medicine
43. Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
    Rodrigo Dienstmann, Pablo Martínez, Enriqueta Felip · 2011 · Oncotarget
44. C-MET as a new therapeutic target for the development of novel anticancer drugs
    Israel Cañadas, Federico Rojo, Montserrat Arumí-Uría, Ana Rovira, Joan Albanell, Edurne Arriola · 2010 · Clinical & Translational Oncology
45. Chromosomal and genomic changes in lung cancer
    Marileila Varella‐Garcia · 2010 · Cell Adhesion & Migration
46. Quantitative Analysis of HGF and EGF-Dependent Phosphotyrosine Signaling Networks
    Dean E. Hammond, Russell Hyde, Irina Kratchmarova, Robert Jeffrey Beynon, Blagoy Blagoev, Michael J. Clague · 2010 · Journal of Proteome Research
47. “Active” Cancer Immunotherapy by Anti-Met Antibody Gene Transfer
    Elisa Vigna, Giovanni Pacchiana, Massimiliano Mazzone, Cristina Chiriaco, Lara Fontani, Cristina Basilico, Selma Pennacchietti, Paolo Maria Comoglio · 2008 · Cancer Research
48. Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro
    Sung-Han Hsiao, Ya-Jui Lin, Yanqing Li, Yang-Hui Huang, Chia‐Hung Hsieh, Chung‐Pu Wu · 2016 · Molecular Pharmaceutics
49. Biomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip Models
    Katya A. D’Costa, Milena Kosic, Angus Lam, Azeen Moradipour, Yimu Zhao, Milica Radisic · 2020 · Annals of Biomedical Engineering
50. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib‐resistant lung cancer growth
    Sung Keun Jung, Mee‐Hyun Lee, Do Young Lim, Sungyoung Lee, Chul‐Ho Jeong, Jong‐Eun Kim, Tae Gyu Lim, Hanyong Chen, Ann M. Bode, Hyong Joo Lee et al. · 2014 · Molecular Carcinogenesis
51. Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients
    Mengmeng Yang, Baoen Shan, Qiaoxia Li, Xiaoming Song, Jie Cai, Jianyun Deng, Likun Zhang, 杜镇建, Junjie Lu, Taiping Chen et al. · 2012 · International Journal of Cancer
52. EGFR Assays in Lung Cancer
    Sanja Đačić · 2008 · Advances in Anatomic Pathology
53. First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    Joel W. Neal, Kim-Son Hoa Nguyen · 2012 · Biologics
54. Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
    Tan Min Chin, Margaret P. Quinlan, Anurag Singh, Lecia Van Dam Sequist, Thomas James Lynch, Daniel A. Haber, Sreenath V. Sharma, Jeffrey E. Settleman · 2008 · Clinical Cancer Research
55. Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation
    Jin Kyung Rho, Yun Jung Choi, Byung-Suk Jeon, Su Jin Choi, Gi Jeong Cheon, Sang‐Keun Woo, Hye-Ryoun Kim, Cheol Hyeon Kim, Chang‐Min Choi, Jae Cheol Lee · 2010 · Molecular Cancer Therapeutics
56. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
    Xu Zhang, Tapan Kumar Maity, Manoj Kumar Kashyap, Mukesh Bansal, Abhilash Karavattu Venugopalan, Sahib Singh, Shivangi Awasthi, Arivusudar Marimuthu, Harrys K.C. Jacob, Natalya Belkina et al. · 2017 · Molecular & Cellular Proteomics
57. Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer
    Florian Malchers, Meryem Seda Ercanoglu, Daniel Schütte, Roberta Castiglione, Verena Tischler, Sebastian Yves Friedrich Michels, Ilona Dahmen, Johannes Brägelmann, Roopika Menon, Johannes M. Heuckmann et al. · 2017 · Clinical Cancer Research
58. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji · 2019 · Seminars in Cancer Biology
59. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
    Peilin Jia, Hailing Jin, Catherine Belle Meador, Junfeng Xia, Kadoaki Ohashi, Lin Liu, Valentina Pirazzoli, Kimberly Brown Dahlman, Katerina A. Politi, Franziska Michor A et al. · 2013 · Genome Research
60. XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib
    Maria Catherine Pietanza, Thomas James Lynch, Primo N. Lara, John Cho, Ronald H. Yanagihara, Nandagopal S. Vrindavanam, Naveed Mahfooz Chowhan, Shirish M. Gadgeel, Nathan A. Pennell, Roel Peter Funke et al. · 2011 · Journal of Thoracic Oncology
61. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
    Surya Kant Tripathi, Kamal Pandey, Kannan R. R. Rengasamy, Bijesh Kumar Biswal · 2020 · Medicinal Research Reviews
62. Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
    Seung Yeon Oh, You Won Lee, Eun Ji Lee, Jae Hwan Kim, YoungJoon Park, Seong Gu Heo, Mi Ra Yu, Min Hee Hong, John O. DaSilva, Christopher Daly et al. · 2022 · Clinical Cancer Research
63. Parallel Evolution under Chemotherapy Pressure in 29 Breast Cancer Cell Lines Results in Dissimilar Mechanisms of Resistance
    Bálint Tegze, Zoltán Szállási, Irén Haltrich, Zsófia Pénzváltó, Zsuzsa Tóth, István Likó, Balázs Győrffy · 2012 · PLoS ONE
64. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
    Sebahat Ocak, Martin L. Sos, Roman Kurt Thomas, Pierre P. Massion · 2009 · European Respiratory Journal
65. Targeting the MET oncogene in cancer and metastases
    Giulia Maria Stella, Silvia Benvenuti, Paolo Maria Comoglio · 2010 · Expert Opinion on Investigational Drugs
66. NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.
    Robert C Black, Humera Khurshid · 2015 · PubMed
67. Resistance to gefitinib and cross‐resistance to irreversible EGFR‐TKIs mediated by disruption of the Keap1‐Nrf2 pathway in human lung cancer cells
    Seong-Hee Park, Jae Hwan Kim, Eunsun Ko, Jeong‐Yub Kim, Myung Jin Park, Jong Min Kim, Hyemin Seo, Shibo Li, Ji-Yun Lee · 2018 · The FASEB Journal
68. Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
    Heiner Koch, M. Estela del Castillo Busto, Karl Kramer, Guillaume Médard, Bernhard Küster · 2015 · Journal of Proteome Research
69. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.
    German G. Gomez, Jill Wykosky, Ciro Zanca, Frank B. Furnari, Webster K. Cavenee · 2013 · Europe PMC (PubMed Central)
70. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients
    Ling Shan, Ziping Wang, Lei Guo, Hongyan Sun, Tian Qiu, Yun Ling, Wenbin Li, Lin Li, Xiuyun Liu, Bo Jian Zheng et al. · 2015 · Lung Cancer
71. Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
    Silvia La Monica, Cristina Caffarra, Francesca Saccani, Elena Galvani, Maricla Galetti, Claudia Fumarola, Mara A. Bonelli, Andrea Cavazzoni, Daniele Cretella, Rita Sirangelo et al. · 2013 · PLoS ONE
72. Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
    Gang Chen, Alfiah Noor, Peter Kronenberger, Erik Teugels, Ijeoma Adaku Umelo, Jacques De Grève · 2013 · PLoS ONE
73. Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside
    Jordi Ahnert Rodon, José Manuel Pérez-García, Razelle Kurzrock · 2010 · The Oncologist
74. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
    Jiannong Li, Keiryn L. Bennett, Alexey Stukalov, Bin Fang, Guolin Zhang, Takeshi Yoshida, Isamu Okamoto, Jae‐Young Kim, Lanxi Song, Yun Bai et al. · 2013 · Molecular Systems Biology
75. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
    Peter B. Alexander, Xiao‐Fan Wang · 2015 · Frontiers of Medicine
76. Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
    Jackie L. Johnson, Smitha Pillai, Srikumar Chellappan · 2012 · Biochemistry Research International
77. Clinical Implications of MET Gene Copy Number in Lung Cancer
    Luca Toschi, Federico Cappuzzo · 2010 · Future Oncology
78. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy
    Darren R. Hargrave · 2009 · British Journal of Neurosurgery
79. MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
    Nandini Dey, Brian R Leyland-Jones, Pradip K. De · 2015 · Europe PMC (PubMed Central)
80. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth
    Linfeng Xu, Xiaoxiao Meng, Naihan Xu, Wenwei Fu, Hongsheng Tan, Li Zhang, Qianjun Zhou, Jianan Qian, Shiwei Tu, Xueting Li et al. · 2018 · Cell Death and Disease
81. Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
    Jennifer Wilkinson Carlisle, Suresh S. Ramalingam · 2019 · Future Oncology
82. The METeoric rise of MET in lung cancer
    Alex Friedlaender, Alexander Edward Dela Cruz Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo · 2020 · Cancer
83. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma
    Seongyeol Park, Jaemoon Koh, Dong‐Wan Kim, Miso Kim, Bhumsuk Keam, Tae‐Min Kim, Yoon Kyung Jeon, Doo Hyun Chung, Dae Seog Heo · 2015 · Lung Cancer
84. The pharmacological point of view of resistance to therapy in tumors
    Giovanna L.M. Damia, Silvio K. Garattini · 2014 · Cancer Treatment Reviews
85. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor
    Naruyuki Kobayashi, Shinichi Toyooka, Junichi Soh, Hiromasa Yamamoto, Hideaki Dote, Kensuke Kawasaki, Hiroki Otani, Takafumi Kubo, Masaru Jida, Tsuyoshi Ueno et al. · 2011 · Lung Cancer
86. Predictive biomarkers in precision medicine and drug development against lung cancer
    Bingliang Fang, Reza John Mehran, John Victor Heymach, Stephen G. Swisher · 2015 · 癌症：英文版
87. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients
    Mina Nikanjam, Sariah Liu, Jincheng Yang, Razelle Kurzrock · 2017 · The Oncologist
88. Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors
    Thomas T. Poulsen, Michael Monrad Grandal, Niels Jørgen Østergaard Skartved, Rikke Hald, Lene Hjorth Alifrangis, Klaus Koefoed, Trine Lindsted, Camilla Fröhlich, Sofie Ellebæk Pollmann, Karsten Wessel Eriksen et al. · 2017 · Clinical Cancer Research
89. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
    Xuexia Tong, Ryosuke Tanino, Rong Sun, Yukari Tsubata, Tamio Okimoto, Mayumi Takechi, Takeshi Isobe · 2019 · Respiratory Research
90. Chemical and Pathway Proteomics
    Ulrich Kruse, Marcus Bantscheff, Gerard Drewes, Carsten Hopf · 2008 · Molecular & Cellular Proteomics
91. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future
    Chih-Hsin Yang · 2008 · Lung Cancer
92. Targeting MET: why, where and how?
    Elena Ghiso, Silvia Giordano · 2013 · Current Opinion in Pharmacology
93. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
    Minghui Liu, Song Xu, Yuli Wang, Ying Li, Li Y, Hongbing Zhang, Hongyu Liu, Jun Chen · 2016 · Oncotarget
94. Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
    Jing Xu, Jinghui Wang, Shucai Zhang · 2017 · Oncotarget
95. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi · 2020 · Expert Opinion on Emerging Drugs
96. Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs
    Jiang, Juhong, Gu, Yingying, Liu, Jing, Wu, Ruibin, Fu, Lin, Zhao, Jin, Guan, Yubao · 2016 · Lung Cancer
97. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
    Xie, Caifeng, Jin, Jiangbo, Bao, Xujie, Zhan, Wei-Hua, Han, Tian-Yu, Gan, Mingxi, Zhang, Chengfu, Wang, Jianbin · 2016 · Oncotarget
98. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer
    Li, Cunxi, Singh, Bhuminder, Graves-Deal, Ramona, Ma, Haiting, Starchenko, Alina, Fry, William H., Lu, Yuanyuan, Wang, Yang, Bogatcheva, Galina, Khan, Mohseen P. et al. · 2017 · Proceedings of the National Academy of Sciences
99. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
    Yi-Qing Qu, Xiuxiu Wu, Yunhong Yin, Yan Yang, Dedong Ma, Hao Li · 2014 · Journal of Experimental & Clinical Cancer Research
100. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
     Manan P. Shah, Joel W. Neal · 2022 · Drugs